undamentalytics Newsletter
Sign in

Vivosim Labs, Inc. income statement

In fiscal 2026, Vivosim Labs, Inc. reported revenue of $131,000, down 9.0% on the year before, operating income of −$11.5m (a -8768.7% margin) and net income of −$13.8m, or −$5.35 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Dec 20102012Dec 20112013Dec 20122014Mar 20142015Mar 20152016Mar 20162017Mar 20172018Mar 20182019Mar 20192020Mar 20202021Mar 20212022Mar 20222023Mar 20232024Mar 20242025Mar 20252026Mar 2026LTMJun 2026
Revenue11101145320200000
Cost of revenue————0011100———00—
Gross profit————1134320———00—
Research and development1138131820181551395544
Selling, general and administrative127131822222115181610910877
Operating income−1−2−9−21−30−39−39−35−27−21−17−11−18−15−13−11−11
Interest expense0210000———————000
Income before tax——————————————−2−14—
Income tax———00000000000000
Net income−1−4−44−26−30−39−38−35−27−19−17−11−17−15−2−14−12
Diluted EPS$0.00$0.00$0.00−$2.10−$45.60−$51.60−$2.34−$38.40−$1.38−$16.80−$14.64−$7.92−$11.88−$9.63−$1.70−$5.35−$3.77
Diluted shares (average)—————————1m1m1m1m2m1m3m3m
EBITDA−1−2−9−20−30−38−37−34−26−20−17−11−17−15−12−11−11

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: IBIO vs VIVSLSTA vs VIVSAIM vs VIVS

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Vivosim Labs, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Vivosim Labs, Inc.